Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey

BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS, Vera VASILYEVA, Juan Gomez RIVAS, Erik BRIERS, Thomas FRESE, Josep VILASECA, Shlomo VINKER, Renata CHLOUPKOVÁ, Ondřej MÁJEK, Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, Hendrik van POPPEL a Monique J ROOBOL. Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey. Journal of Personalized Medicine. Basel: MDPI, 2024, roč. 14, č. 7, s. 1-12. ISSN 2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm14070751.

Základní údaje

• Originální název: Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey
• Autoři: BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS, Vera VASILYEVA, Juan Gomez RIVAS, Erik BRIERS, Thomas FRESE, Josep VILASECA, Shlomo VINKER, Renata CHLOUPKOVÁ (203 Česká republika, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, Hendrik van POPPEL a Monique J ROOBOL.
• Vydání: Journal of Personalized Medicine, Basel, MDPI, 2024, 2075-4426.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30204 Oncology
• Stát vydavatele: Švýcarsko
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 3.508 v roce 2021
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.3390/jpm14070751
• UT WoS: 001276999500001
• Klíčová slova anglicky: barriers; early detection; population-based screening; prostate cancer
• Štítky: 14119612, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. Methods: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach. Results: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers). Conclusions: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.